Effect of Lactobacillus Reuteri DSM 17938 to Prevent Antibiotic-associated Diarrhea in Children

PHASE4CompletedINTERVENTIONAL
Enrollment

1,325

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

July 1, 2020

Study Completion Date

December 1, 2020

Conditions
Antibiotic Associated Diarrhea
Interventions
DRUG

Lactobacillus reuteri DSM 17938

Comparison the effects of Lactobacillus reuteri DSM 17938 and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on efficacy.

DRUG

Placebo

Comparison the effects of Lactobacillus reuteri DSM 17938 and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on

DRUG

Amoxicillin-Clavulanic Acid

All study patients will received amoxicillin-clavulanic acid at the dose of 50-90 mg/kg/day.

Trial Locations (1)

34000

Sisli Etfal Training and Research Hospital,, Istanbul

All Listed Sponsors
collaborator

Hacettepe University

OTHER

collaborator

Acıbadem University School of Medicine

OTHER

collaborator

Umraniye Education and Research Hospital

OTHER_GOV

collaborator

Sisli Hamidiye Etfal Training and Research Hospital

OTHER

collaborator

Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization

OTHER

collaborator

Ege University Medical School

OTHER

collaborator

Yuzuncu Yıl University

OTHER

collaborator

Goztepe Training and Research Hospital

OTHER

collaborator

Erzurum Regional Training & Research Hospital

OTHER_GOV

collaborator

Namik Kemal University

OTHER

lead

Eskisehir Osmangazi University

OTHER

NCT02765217 - Effect of Lactobacillus Reuteri DSM 17938 to Prevent Antibiotic-associated Diarrhea in Children | Biotech Hunter | Biotech Hunter